CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
42.4%
6M of 14M shares
Institutional holders
28
4 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Morgan Duke | 882,581 | 6.49% | 13G (passive) amendment | Sep 30, 2024 |
| Anthony A. Florence, Jr. | 1,713,720 | – | 13D (active) amendment | Mar 15, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CSBR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Battery Management Corp. | 2,421,673 | 17.40% | $14.92M | – | 4.05% |
| NEA Management Company, LLC | 1,713,720 | 12.31% | $10.56M | – | 0.66% |
| Vanguard Capital Management LLC | 301,353 | 2.17% | $1.86M | +1,833 | 0.00% |
| Tocqueville Asset Management L.P. | 295,658 | 2.12% | $1.82M | −24,016 | 0.02% |
| Morgan Stanley | 235,400 | 1.69% | $1.45M | −6,900 | 0.00% |
| Bank Of America Corp /De/ | 214,058 | 1.54% | $1.32M | +192,225 | 0.00% |
| Renaissance Technologies LLC | 139,039 | 1.00% | $856.48K | −6,500 | 0.00% |
| BlackRock, Inc. | 129,848 | 0.93% | $799.86K | +5,948 | 0.00% |
| Mink Brook Asset Management LLC | 111,338 | 0.80% | $685.84K | – | 0.30% |
| Geode Capital Management, LLC | 76,300 | 0.55% | $470.12K | −877 | 0.00% |
| HighTower Advisors, LLC | 41,901 | 0.30% | $258.11K | +6,743 | 0.00% |
| Vanguard Fiduciary Trust Co | 33,239 | 0.24% | $204.75K | +247 | 0.00% |
| Northern Trust Corp | 27,910 | 0.20% | $171.93K | −18,022 | 0.00% |
| State Street Corp | 26,203 | 0.19% | $161.41K | – | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 24,504 | 0.18% | $150 | +12,252 | 0.00% |
| Bank of New York Mellon Corp | 21,614 | 0.16% | $133.14K | – | 0.00% |
| Acadian Asset Management LLC | 20,523 | 0.15% | $125 | −800 | 0.00% |
| Citadel Advisors LLC | 18,295 | 0.13% | $112.70K | New | 0.00% |
| Essex Investment Management Co LLC | 18,221 | 0.13% | $112.24K | −28 | 0.01% |
| Mesirow Financial Investment Management, Inc. | 15,800 | 0.11% | $97.33K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 6M | 42.4% | 4 / 6 | 7 / 1 | 0M | 0M |
| Q1 2026 | 25 | 6M | 41.2% | 4 / 5 | 6 / 5 | 0M | 0M |
| Q4 2025 | 27 | 6M | 41.3% | 3 / 7 | 8 / 3 | 0M | 0M |
| Q3 2025 | 27 | 6M | 40.7% | 2 / 5 | 10 / 5 | 0M | 0M |
| Q2 2025 | 30 | 6M | 41.5% | 4 / 8 | 7 / 8 | 0M | 0M |
| Q1 2025 | 34 | 6M | 42.5% | 10 / 10 | 6 / 1 | 0M | 0M |
| Q4 2024 | 25 | 6M | 41.1% | 6 / 6 | 4 / 3 | 0M | 0M |
| Q3 2024 | 22 | 6M | 41.6% | 3 / 7 | 3 / 3 | 0M | 0M |
| Q2 2024 | 23 | 6M | 41.5% | 0 / 6 | 8 / 2 | 0M | 0M |
| Q1 2024 | 25 | 6M | 41.1% | 5 / 6 | 9 / 3 | 0M | 0M |
| Q4 2023 | 23 | 6M | 40.4% | 0 / 8 | 7 / 5 | 0M | 0M |
| Q3 2023 | 29 | 6M | 41.2% | 3 / 4 | 10 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CSBR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 229,971 | 1.65% | $1.42M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 62,775 | 0.45% | $386.69K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 32,203 | 0.23% | $188.39K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 28,454 | 0.20% | $175.28K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 12,140 | 0.09% | $71.02K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 10,958 | 0.08% | $64.10K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,232 | 0.07% | $54.01K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 6,854 | 0.05% | $36.74K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 6,527 | 0.05% | $40.21K | 0.00% | Jun 30, 2026 |
| Small Cap Core Fund | 4,471 | 0.03% | $27.54K | 0.01% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 2,080 | 0.01% | $12.81K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 2,034 | 0.01% | $12.53K | 0.01% | Jun 30, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 279 | 0.00% | $1.72K | 0.00% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 149 | 0.00% | $918 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Lawrence Brainin | CEO, Director | – | – | Jan 30, 2026 |
| David Sidransky | Director | 767,043 | 5.51% | Nov 7, 2025 |
| Scott R. Tobin | Director, 10% owner | 2,041,882 | 14.67% | Nov 7, 2025 |
| Joel Ackerman | Director | 1,056,539 | 7.59% | Nov 7, 2025 |
| Daniel Newman Mendelson | Director | 298,625 | 2.15% | Nov 7, 2025 |
| Philip P. Breitfeld | Director | 5,717 | 0.04% | Nov 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joel Ackerman Director | Oct 30, 2025 | Option exercise | +94,405 | $2.10 | $198.25K | 1,056,539 |
| Philip P. Breitfeld Director | Mar 25, 2025 | Other | −4,150 | – | – | 5,717 |
| Joel Ackerman Director | Oct 31, 2024 | Option exercise | +88,470 | $2.10 | $185.79K | 945,467 |
| Joel Ackerman Director | Oct 31, 2024 | Option exercise | +16,667 | $5.43 | $90.50K | 962,134 |
| Daniel Newman Mendelson Director | Jan 12, 2024 | Buy | +1,000 | $6.50 | $6.50K | 198,625 |
| Daniel Newman Mendelson Director | Jan 11, 2024 | Buy | +2,000 | $6.27 | $12.54K | 197,625 |
| Daniel Newman Mendelson Director | Jan 10, 2024 | Buy | +2,944 | $6.31 | $18.58K | 195,625 |
| Daniel Newman Mendelson Director | Jan 9, 2024 | Buy | +3,000 | $6.25 | $18.75K | 192,681 |
| Daniel Newman Mendelson Director | Jan 8, 2024 | Buy | +1,000 | $6.15 | $6.15K | 189,681 |
| Daniel Newman Mendelson Director | Jan 5, 2024 | Buy | +2,000 | $6.09 | $12.18K | 188,681 |
| Daniel Newman Mendelson Director | Jan 4, 2024 | Buy | +3,000 | $6.12 | $18.36K | 186,681 |
| Daniel Newman Mendelson Director | Jan 3, 2024 | Buy | +500 | $5.83 | $2.92K | 183,681 |
| Daniel Newman Mendelson Director | Dec 21, 2023 | Buy | +2,500 | $4.92 | $12.30K | 183,181 |
| Daniel Newman Mendelson Director | Dec 20, 2023 | Buy | +2,100 | $4.82 | $10.12K | 180,681 |
| Daniel Newman Mendelson Director | Dec 19, 2023 | Buy | +5,000 | $4.75 | $23.75K | 178,581 |
| Joel Ackerman Director | Oct 17, 2023 | Option exercise | +114,552 | $2.10 | $240.56K | 856,997 |
| Daniel Newman Mendelson Director | Oct 11, 2023 | Buy | +5,000 | $6.40 | $32.00K | 163,081 |
| Daniel Newman Mendelson Director | Oct 10, 2023 | Buy | +1,100 | $6.41 | $7.05K | 158,081 |
| Daniel Newman Mendelson Director | Oct 6, 2023 | Buy | +1,530 | $6.48 | $9.91K | 156,981 |
| Daniel Newman Mendelson Director | Oct 5, 2023 | Buy | +2,000 | $6.47 | $12.94K | 155,451 |
| Daniel Newman Mendelson Director | Oct 4, 2023 | Buy | +5,000 | $6.40 | $32.00K | 153,451 |
| Daniel Newman Mendelson Director | Oct 3, 2023 | Buy | +2,500 | $6.30 | $15.75K | 148,451 |
| Daniel Newman Mendelson Director | Sep 29, 2023 | Buy | +4,000 | $6.16 | $24.64K | 173,581 |
| Daniel Newman Mendelson Director | Sep 28, 2023 | Buy | +5,000 | $6.22 | $31.10K | 169,581 |
| Daniel Newman Mendelson Director | Sep 27, 2023 | Buy | +1,500 | $5.95 | $8.93K | 164,581 |
| Daniel Newman Mendelson Director | Sep 26, 2023 | Buy | +5,000 | $5.65 | $28.25K | 145,951 |
| Daniel Newman Mendelson Director | Sep 22, 2023 | Buy | +3,812 | $5.50 | $20.97K | 140,951 |
| Daniel Newman Mendelson Director | Sep 21, 2023 | Buy | +5,000 | $5.51 | $27.55K | 137,139 |
| Daniel Newman Mendelson Director | Sep 20, 2023 | Buy | +4,018 | $5.51 | $22.14K | 132,139 |
| Daniel Newman Mendelson Director | Sep 19, 2023 | Buy | +5,000 | $5.28 | $26.40K | 128,121 |
| Ronnie Morris CEO, Director | Mar 17, 2023 | Buy | +12,382 | $4.04 | $50.02K | 858,878 |
| Joel Ackerman Director | Oct 19, 2022 | Option exercise | +16,667 | $3.21 | $53.50K | 1,460,595 |
| David Sidransky Director | Oct 12, 2022 | Tax withholding | −3,562 | $7.51 | $26.75K | 767,043 |
| David Sidransky Director | Oct 12, 2022 | Option exercise | +8,333 | $3.21 | $26.75K | 770,605 |
| Philip P. Breitfeld Director | Oct 12, 2022 | Option exercise | +8,333 | $3.21 | $26.75K | 18,200 |
| Philip P. Breitfeld Director | Oct 12, 2022 | Tax withholding | −3,562 | $7.51 | $26.75K | 14,638 |
| Scott R. Tobin Director | Oct 12, 2022 | Option exercise | +10,000 | $3.21 | $32.10K | 30,000 |
| David Sidransky Director | Oct 15, 2021 | Tax withholding | +2,629 | $10.08 | $26.50K | 762,272 |
| David Sidransky Director | Oct 15, 2021 | Option exercise | +16,667 | $1.59 | $26.50K | 764,901 |
| Scott R. Tobin Director | Oct 12, 2021 | Option exercise | +10,000 | $1.59 | $15.90K | 20,000 |
| Philip P. Breitfeld Director | Mar 23, 2021 | Option exercise | +4,167 | $3.65 | $15.21K | 4,167 |
| Philip P. Breitfeld Director | Mar 23, 2021 | Tax withholding | −1,340 | $11.35 | $15.21K | 2,827 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $3.21 | $32.10K | 80,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $5.43 | $54.30K | 90,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Option exercise | +10,000 | $1.59 | $15.90K | 70,147 |
| Abba David Poliakoff Director | Jan 19, 2021 | Tax withholding | +8,873 | $11.53 | $102.31K | 81,274 |
| Philip P. Breitfeld Director | Dec 16, 2020 | Sale | −31,443 | $11.35 | $356.88K | 0 |
| Scott R. Tobin Director | Oct 30, 2020 | Option exercise | +10,000 | $5.46 | $54.60K | 10,000 |
| David Sidransky Director | Oct 16, 2020 | Tax withholding | −10,100 | $9.01 | $91.00K | 748,234 |
| David Sidransky Director | Oct 16, 2020 | Option exercise | +16,667 | $5.46 | $91.00K | 758,334 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +100 | $5.99 | $599 | 57,646 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +20 | $6.00 | $120 | 57,546 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +700 | $5.90 | $4.13K | 58,446 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +100 | $5.97 | $597 | 57,746 |
| Daniel Newman Mendelson Director | Mar 26, 2020 | Buy | +300 | $5.89 | $1.77K | 58,746 |
| Daniel Newman Mendelson Director | Mar 24, 2020 | Buy | +26 | $5.50 | $143 | 57,526 |
| Ronnie Morris CEO, Director | Mar 24, 2020 | Sale | −75 | $5.25 | $394 | 837,168 |
| Ronnie Morris CEO, Director | Mar 20, 2020 | Buy | +75 | $4.75 | $356 | 837,243 |
| Ronnie Morris CEO, Director | Mar 11, 2020 | Option exercise | +2,708 | $4.80 | $13.00K | 964,108 |
| Ronnie Morris CEO, Director | Mar 11, 2020 | Option exercise | +124,232 | $5.76 | $715.58K | 961,400 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.